FOLD News and Press, Amicus Therapeutics Inc. From 09/20/21

PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (WMS) being held virtually, ...

PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: Morgan Stanley 19 th Annua...

Amicus Therapeutics, Inc. (FOLD) Q2 2021 Earnings Conference Call August 5, 2021 08:00 ET Company Participants Andrew Faughnan - Head, Investor Relations John Crowley - Chairman and Chief Executive Officer Bradley Campbell - President and Chief Operating Officer Daphne Quimi - Chief Financial...

Image source: The Motley Fool. Amicus Therapeutics, inc (NASDAQ: FOLD) Q2 2021 Earnings Call Aug 5, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript

2Q21 Total Galafold ® (migalastat) Revenue of $77.4M, a 24% increase over 2Q20 On-Track to Achieve Revenue Guidance of $300M-$315M Completed the Rolling BLA and NDA Submissions to the U.S. FDA for AT-GAA in Pompe Disease ...

Amicus Therapeutics (NASDAQ:FOLD) perks up 3.6% premarket after announcing that the European Commission (EC) has approved Galafold (migalastat) for use in adolescents aged 12 to <16 years weighing ≥ 45 kg with a confirmed diagnosis of Fabry disease and who have a...

PHILADELPHIA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Commission has approved Galafold &...

PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021. I...

Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) traded at a new 52-week low today of $8.62. So far today approximately 404,000 shares have been exchanged, as compared to an average 30-day volume of 2.2 million shares. Amicus Therapeutics Inc is a biotechnology company focused on discove...

Hailshadow/iStock via Getty Images Citing expert opinion on the company’s experimental therapy for Pompe disease, BTIG has assumed a buy rating on Amicus Therapeutics ([[FOLD]] +0.3%). In February, the company failed to meet the primary endpoint in a Phase 3 trial for AT-GAA (cipagluco...